Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154072 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
A Phase 2 study, sponsored by Neuraly.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT04154072 is a Phase 2 study that has completed, run by Neuraly. The registered enrollment target is 255 participants.
The verdict
NCT04154072, a Phase 2 study, has completed, sponsored by Neuraly.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.
Interventions
- DRUG Vehicle
- DRUG NLY01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04154072
The ClinicalTrials.gov registry entry for NCT04154072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuraly, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04154072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04154072 about?
NCT04154072 is a clinical study titled "A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease". This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative d...
What is the current status of trial NCT04154072?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2020-02-27. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT04154072?
The interventions under investigation include: Vehicle (DRUG), NLY01 (DRUG).
Who is sponsoring clinical trial NCT04154072?
This trial is sponsored by Neuraly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.